- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01990053
Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Currently, outpatient psychiatric settings are plagued by long wait times and are often unable to accommodate all individuals seeking services. Furthermore, a lack of trained therapists in these settings means that many treatment seekers do not have access to empirically supported psychotherapeutic treatments such as cognitive behavioral therapy. "Beating the Blues" (BtB) is a computerized, internet-delivered, cognitive behavioral treatment for depression. BtB is highly scalable and might enable a larger proportion of individuals to receive cognitive behavioral therapy in a psychiatric setting while also reducing therapist time. Although computerized CBT interventions have proven effective in primary care settings, there is no research demonstrating the effectiveness of cCBT in secondary care settings in the United States. Thus the primary goal of the proposed research is to test the efficacy of BtB in a specialty care sample.
Patients presenting to these settings tend to have more severe and complex psychopathology than those presenting to primary care. Although BtB is likely effective, computerized treatments do carry a higher risk of dropout and non-response. Therefore, reliable and valid predictors of response are needed to determine who is most likely to respond to the treatment, versus who is likely to fail or drop out. Thus the second aim of the current proposal is to pilot an assessment procedure containing a number of potential predictors of cCBT response and investigate these predictors for inclusion in a larger validation study.
The current trial is a pilot study with a randomized waitlist control design with optional delayed treatment for individuals randomized to the waitlist condition. For the first phase, the investigators will enroll 90 treatment-seeking adults 18 or older recruited from a pool of individuals seeking outpatient psychiatric services at a hospital clinic. Sixty (n=60) individuals will be assigned immediate treatment group with BtB plus telephone and email support, and n=30 to the waitlist/delayed BtB plus telephone and email support group. Efficacy will be assessed over 8 weeks using the Hamilton Rating Scale for Depression (pre to post treatment) and the PHQ9 (measured at weeks 1-8). There will also be a 1-year follow-up survey with biweekly symptom assessments throughout the year for treatment responders (weeks 9-61). Potential predictors of outcome include demographics, CBT skills, personality measures, cognitive functioning, measures of attitudes and beliefs, social functioning, psychiatric comorbidity and depression illness characteristics, and psychophysiological measures. A second phase will enroll sixty individuals (n=60), who will be assigned immediate treatment group in order to validate the predictive model constructed during Phase 1.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of Major Depressive Disorder (MDD) according to Diagnostic and Statistical Manual Fourth Edition criteria
- Able and willing to give informed consent
- Have access to a computer with an internet connection at home
Exclusion Criteria:
- History of bipolar affective disorder or psychosis
- Current Axis I disorder other than MDD if it constitutes the predominate aspect of the clinical presentation and if it requires treatment other than that being offered
- History of substance dependence in the past six months
- Subnormal intellectual potential (IQ below 80)
- Clear indication of secondary gain (e.g., court ordered treatment or compensation issues)
- Current suicide risk or significant intentional self-harm in the last six months sufficient to preclude treatment on an outpatient basis
- Discharge within six moths from a higher level of care (inpatient, partial hospital, or intensive outpatient treatment)
- Currently undergoing outpatient psychotherapy
- Current antidepressant medication treatment if the individual has had a change in medication over the past month or is planning a change in medication during the duration of the study
- Inability to read and write English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Beating the Blues
Beating the Blues plus helper support.
|
The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression.
Support will be provided by licensed professional therapists over the phone or via email.
Other Names:
|
|
No Intervention: Waitlist Condition
Eight week waitlist condition group parallel to the immediate treatment condition with optional entrance into the Beating the Blues after the first eight weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Hamilton Rating Scale for Depression (HRSD) from 0 to 8 weeks
Time Frame: week 0, week 8
|
The 17-item HRSD, modified to assess atypical symptoms, is a standard interview-administered measure of depressive symptom severity.
The HRSD will be administered by study personnel supervised by the Principal Investigator.
|
week 0, week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Patient Health Questionnaire-9 (PHQ9) over 8 weeks
Time Frame: weeks 0-8
|
The PHQ9 is a 9-item self-report measure based on the diagnostic criteria for major depression from the Diagnostic and Statistical Manual Fourth Edition (DSM-IV).
|
weeks 0-8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Generalized Anxiety Disorder-7 (GAD7) over 8 weeks
Time Frame: weeks 0-8
|
The GAD7 is a 7-item self-report measure based on the diagnostic criteria for generalized anxiety disorder from the DSM-IV.
|
weeks 0-8
|
|
Change in Depression Anxiety and Stress Scale-21 (DASS21) over 8 weeks
Time Frame: week 0, week 8
|
The DASS21 is a 21-item self-report scale measuring symptoms of depression, anxiety, and stress.
|
week 0, week 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniel R Strunk, PhD, Ohio State University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013B0307
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Gang WangWest China Hospital; The First Hospital of Hebei Medical University; Tianjin... and other collaboratorsRecruitingMajor Depressive Disorder (MDD) | Depression - Major Depressive DisorderChina
-
Brian MickeyNational Institute of Mental Health (NIMH)RecruitingMajor Depressive Episode | Depression - Major Depressive Disorder | Treatment-Resistant Major Depressive DisorderUnited States
-
Second Affiliated Hospital of Tsinghua UniversityNot yet recruiting
-
First People's Hospital of HangzhouNot yet recruitingMajor Depressive Disorder
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Recruiting
-
Shandong Provincial HospitalShandong UniversityRecruiting
-
Engrail Therapeutics INCCompletedMajor Depressive DisorderUnited Kingdom
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Aalborg University HospitalRecruitingDepressive Disorder | Depression | Depressive Episode | Depressive Disorders | Depressive Episodes | Depression - Major Depressive Disorder | Depressive Disorder, Major Depressive DisorderDenmark
-
Unity Health TorontoUniversity of Toronto; Toronto Metropolitan UniversityRecruitingMajor Depressive Disorder (MDD) | Major Depressive Episode | Treatment-Resistant Major Depressive DisorderCanada
Clinical Trials on Beating the Blues
-
University of MichiganCompletedDepressionUnited States
-
University of Michigan Rogel Cancer CenterSt. Baldrick's FoundationTerminatedCancer | Depression, AnxietyUnited States
-
University of PittsburghNational Institute of Nursing Research (NINR)CompletedPrimary Malignant Brain TumorsUnited States
-
Indiana UniversityCompleted
-
University of SheffieldSheffield Teaching Hospitals NHS Foundation Trust; Walton Centre NHS Foundation...CompletedDepression | Multiple SclerosisUnited Kingdom
-
Ohio State University Comprehensive Cancer CenterCompletedMajor Depressive DisorderUnited States
-
University of PittsburghCompletedDepression | Anxiety | Sickle Cell DiseaseUnited States
-
Indiana UniversityAmerican Heart AssociationCompletedDepression | Depressive Symptoms | Heart Disease | Coronary Artery Disease (CAD) | Cardiovascular Disease (CVD)United States
-
Xiang WeiFudan University; Guangdong Provincial People's Hospital; Beijing Anzhen Hospital and other collaboratorsRecruitingHypertrophic Obstructive CardiomyopathyChina
-
Xiang WeiRecruitingNonobstructive Hypertrophic CardiomyopathyChina